Initial FDA Approval for Ruxolitinib
Ruxolitinib (brand name Jakafi) received its first FDA approval on November 16, 2011, for intermediate or high-risk myelofibrosis.[1]
First Generic Ruxolitinib Approval
The FDA approved the first generic version of ruxolitinib tablets (15 mg and 20 mg strengths) on October 27, 2023, to Incyte Corporation under Paragraph IV challenges to brand exclusivity. This followed the expiration of pediatric exclusivity on October 23, 2023.[2][3]
Timeline to Generic Entry
- Patent Expiry: Key Orange Book patents for Jakafi expired between 2023 and 2028, enabling ANDA approvals after Hatch-Waxman litigation.
- Market Launch: Incyte's authorized generic launched immediately after approval on October 27, 2023. Other generics from Dr. Reddy's Laboratories, Celltrion, and MSN Laboratories were approved later in December 2023 and January 2024.[4]
- Check DrugPatentWatch.com for full patent and exclusivity timelines.
Availability of Other Forms
Generic topical ruxolitinib cream (Opzelura, 1.5%) was approved October 4, 2024, for vitiligo and atopic dermatitis in patients 12+ years.[5] Oral suspension generic is not yet approved as of late 2024.
Impact on Pricing and Access
Generics entered at about 80-90% lower list price than Jakafi ($12,300/month brand vs. ~$1,500/month generic), improving access for myelofibrosis and polycythemia vera patients.[6]
Sources
[1] FDA.gov - Jakafi Approval History: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202327lbl.pdf
[2] FDA.gov - First Generic Approval Paragraph IV: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-first-generic-jakafi-ruxolitinib-tablets-myelofibrosis-polycythemia-vera
[3] Drugs.com - Ruxolitinib Generic Timeline: https://www.drugs.com/availability/generic-jakafi.html
[4] DrugPatentWatch.com - Jakafi Patents: https://www.drugpatentwatch.com/p/tradename/JAKAFI
[5] FDA.gov - Opzelura Generic: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-generic-opzelura-ruxolitinib-cream
[6] IQVIA Data via FiercePharma - Generic Pricing: https://www.fiercepharma.com/pharma/incyte-launches-authorized-generic-jakafi-slash-price-85